Main areas of research

Identification of genetic, endogenous and environmental risk factors for hormone-sensitive disease

Active investigators

Jacques Simard, Francine Durocher, Marie-Claude Vohl, Louis Pérusse, Vincent Raymond, Chantal Guillemette, Olivier Barbier and Pierre Julien

For a targeted therapeutic approach

Genomic and genetic epidemiology studies are done to identify genetic risk factors and their interactions with other genes and hormonal or environmental factors involved in the susceptibility to breast, ovarian and prostate cancer within a CIHR clinical research network "CIHR Team in Familial Risks of Breast Cancer" as well as endometrial cancer in collaboration with the "Nurses Heath Study and the Women’s Health Study". The goal of these international studies is to develop risk prediction models, improve interventions in risk reduction and develop therapeutic approaches that are better adapted to the different categories of patients.

A multicentric clinical research program

Other investigators use similar approaches in order to better understand the genetic and endogenous determinants and their regulation by nutritional compounds on the physiopathology of obesity and adjustment to exercise as well as their effects on the principal risk factors of cardiovascular disease and diabetes. Studies have also been performed to evaluate the effect of pharmacological and nutritional interventions on the sensitivity of insulin and glucose tolerance, in order to characterize the hormonal factors involved in gestational diabetes. A multicentric research program (IRNPQEO: 6700 subjects), involving the implementation of a biobank (1.5 million aliquots), was developed in order to study the risk factors (genetic, hormonal, nutritional and environmental) involved in the physiopathological conditions associated with oxidative stress. Because of the nature of their work, many investigators are actively involved in the CARTaGENE project, an infrastructure that will facilitate populational genomic research.

Intersectorial research to accelerate the development of knowledge will help healthcare officials to decide on recommendations about diagnostic genetics and changes in the treatment of participants in clinical studies in light of the most recent genetic discoveries.